The toxicology of perfluorooctanoate

Critical Reviews in Toxicology

Volumn 34, Issue 4, 2004, Pages 351-384

  Kennedy Jr , Gerald L ^a   Butenhoff, John L ^b   Olsen, Geary W ^b   O'Connor, John C ^a   Seacat, Andrew M ^b   Perkins, Roger G ^b   Biegel, Lisa B ^c   Murphy, Sandra R ^d   Farrar, David G ^e  

^a DUPONT COMPANY   (United States)

^b 3M COMPANY   (United States)

^c 206 Carnegie Center   (United States)

^d Atofina   (United States)

^e Ineos Manufacturing Scotland Limited   (United Kingdom)

Author keywords

Leydig cell tumor; Liver tumor; Pancreatic acinar cell tumor; Perfluorooctanoate; Peroxisome proliferation; PFOA

Indexed keywords

CYTOCHROME P450; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PERFLUOROOCTANE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ACINAR CELL CARCINOMA; BREAST TUMOR; CARCINOGENESIS; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG EXCRETION; DRUG TISSUE LEVEL; ESTRADIOL BLOOD LEVEL; EYE IRRITATION; FATTY ACID OXIDATION; GENETIC TOXICOLOGY; HAMSTER; HEALTH SURVEY; HUMAN; LEYDIG CELL TUMOR; LIPID METABOLISM; LIVER CELL CARCINOMA; MEDICAL RESEARCH; MONKEY; NONHUMAN; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HEALTH; RABBIT; RECEPTOR AFFINITY; REPRODUCTIVE TOXICITY; REVIEW; SEX DIFFERENCE; SKIN IRRITATION; SKIN SENSITIZATION; SKIN TOXICITY; STATISTICAL SIGNIFICANCE; TOXICOLOGY;

ANIMALS; FEMALE; FLUOROCARBONS; HUMANS; LEYDIG CELL TUMOR; LIVER NEOPLASMS; MALE; MUTAGENICITY TESTS; OCTANOIC ACIDS; PANCREATIC NEOPLASMS; PEROXISOME PROLIFERATORS; RATS; SKIN; TESTICULAR NEOPLASMS; TISSUE DISTRIBUTION;

CRICETINAE; ORYCTOLAGUS CUNICULUS;

EID: 1242311734     PISSN: 10408444     EISSN: None     Source Type: Journal    
DOI: 10.1080/10408440490464705     Document Type: Review

References (187)

1. Abdellatif, A.C., Preat, V., Taper, H.S., and Roberfroid, M. (1991). The modulation of rat liver carcinogenesis by perfluorooctanoic acid, a peroxisome proliferator. Toxicol. Appl. Pharmacol. 111:530-537.
2. Alexander, B.H. (2001). Mortality study of workers employed at the 3M Cottage Grove facility. St. Paul, MN: 3M Company. U.S. EPA Public Docket AR-226-1030a018, Washington, D.C.
3. Alexander, B.H., Olsen, G.W., Burris, J.M., Mandel, J.H., and Mandel, J.S. (2003). Mortality of employees of a perfluorooctanesulphonyl fluoride manufacturing facility. Occup. Environ. Med. 60:722-729.
4. Anderson, K.E., Potter, J.D., and Mack, T.M. (1996). Pancreatic cancer. In Cancer epidemiology and prevention, eds. O. Schottenfeld and J. Fraumeni, pp. 725-771. New York: Oxford University Press.
5. Armstrong, F.H., and Lowe, K.C. (1989). Effects of emulsified perfluorochemicals on liver CYP450 in rats. Comp. Biochem. Physiol. 94C:345-349.
6. Ashby, J., and LeFevre, P.A. (2000). The peripubertal male rat assay as an alternative to the Hershberger castrated male rat assay for the detection of anti-androgens, oestrogens, and metabolic modulators. J. Appl. Toxicol. 20:35-47.
7. Ashby, J., Brady, A., Elcombe, C.R., Elliott, B.M., Ishmael, J., Odum, J., Tugwood, J.D., Kettle, S., and Purchase, I.F.H. (1994). Mechanistically- based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. Hum. Exp. Toxicol. 13(suppl. 2):S1-S117.
8. Belisle, J., and Hagen, D. (1980). A method for determination of perfluorooctanoic acid in blood and other biological samples. Anal. Biochem. 101:369-376.
9. Bentley, P., Calder, I., Elcombe, C., Grasso, P., Stringer, D., and Wiegand, H.-J. (1993). Hepatic peroxisome proliferation in rodents and its significance for humans. Food Chem. Toxicol. 31:857-907.
10. Berthiaume, J., and Wallace, K.B. (2002). Perfluorooctanoate, perfluorooctane sulfonate, and N-ethylperfluorooctanesulfonamido ethanol; Peroxisome proliferation and mitochondrial biogenenesis. Toxicol. Lett. 129:23-32.
11. Biegel, L.B., Liu, R.C.M., Hurtt, M.E., and Cook, J.C. (1995). Effects of ammonium perfluorooctanoate on Leydig cell function: In vitro, in vivo, and ex vivo studies. Toxicol. Appl. Pharmacol. 134:18-25.
12. Biegel, L.B., Hurtt, M.E., Frame, S.R., O'Connor, J.C., and Cook, J.C. (2001). Mechanisms of extrahepatic tumor induction by peroxisome proliferators in male CD rats. Toxicol. Sci. 60:44-55.
13. Burris, J.M., Lundberg, J.K., Olsen, G., Simpson, C., and Mandel, J. (2002). Interim report No. 2, Determination of serum half-lives of several fluorochemicals. St. Paul (MN), 3M Company. U.S. EPA Public Docket AR-226.
14. Butenhoff, J., Costa, G., Elcombe, C., Farrar, D., Hansen, K., Iwai, H., Jung, R., Kennedy, G., Lieder, P., Olsen, G., and Thomford, P. (2002). Toxicity of ammonium perfluorooctanoate (APFO) in male cynomolgus monkeys after oral dosing for six months. Toxicol. Sci. 69:244-257.
15. Butenhoff, J.L., Gaylor, D.W., Moore, J.A., Olsen, G.W., Rodricks, J., Mandel, J.H., and Zobel, L.R. (2004a). Characterization of risk for general population exposure to perfluorooctanoate. Regul. Tox. Pharmacol. 39:363-380.
16. Butenhoff, J.L., Kennedy, G.L., Frame, S.R., O'Connor, J.C., and York, R.G. (2004b). The reproductive toxicology of ammonium perfluorooctanoate (APFO) in the rats. Toxicology 196:95-116.
17. Cameron, R.G., Imaida, K., Tsuda, H., and Ito, N. (1982). Promotive effects of steroids and bile acids on hepatocarcinogenesis initiated by diethylnitrosamine. Cancer Res. 42:2426-2428.
18. Carney, E.W., Scortichini, B.S., and Crissman, J.W. (1998). Feed restriction during in utero and neonatal life: Effects on reproductive and developmental endpoints in the CD rat. Toxicologist 42:102-103.
19. Cattley, R.C., DeLuca, J., Elcombe, C., Fenner-Crisp, P., Lake, B.G., Marsman, D.S., Pastoor, T.A., Popp, J.A., Robinson, D.E., Schweiz, B., Tugwood, J., and Wahli, W. (1998). Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans. Regul. Toxicol. Pharmacol. 27:47-60.
20. Christian, M.S., McCarty, R.J., Cox-Sica, D.K., and Cao, C.P. (1987). Recent increases in the incidences of skull, lung and rib alterations in vehicle control New Zealand white rabbits. J. Am. Coll. Toxicol. 6:562.
21. Clark, R.L. (1999). Endpoints of reproductive system development. In An evaluation and interpretation of reproductive endpoints for human risk assessment, pp. 27-62. Washington, DC: International Life Sciences Institute, Health and Environmental Science Institute.
22. Clegg, E.D., Cook, J.C., Chapin, R.E., Foster, P., and Daston, G.P. (1997). Leydig cell hyperplasia and adenoma formation: Mechanisms and relevance to humans (abstract). Reprod. Toxicol. 11:107-121.
23. Cook, J.C., Murray, S.M., Frame, S.R., and Hurtt, M.E. (1992). Induction of Leydig cell adenomas by ammonium perfluorooctanoate: A possible endocrine-related mechanism. Toxicol. Appl. Pharmacol. 113:209-217.
24. Cook, J.C., Hurtt, M.E., Frame, S.R., and Biegel, L.B. (1994). Mechanisms of extrahepatic tumor induction by peroxisome proliferators in Crl:CDCircled latin capital letter RBR (CD) rats. Toxicologist 14:301.
25. Cook, J.C., Klinefelter, G.R., Hardisty, J.F., Sharpe, R.M., and Foster, P.M. (1999). Rodent Leydig cell tumorigenesis: A review of the physiology, pathology, mechanisms, and relevance to humans. Crit. Rev. Toxicol. 29:169-261.
26. Corton, J., Bocos, C., Moreno, E., Merritt, A., Cattley, R., and Gustafsson, J.A. (1997). Peroxisome proliferators alter the expression of estrogen-metabolizing enzymes. Biochimie 79:151-162.
27. Davis, J.W. II, Vanden Heuvel, J.P., Kuslikis, B.I., and Peterson, R.E. (1991). Castration increases elimination of perfluorooctanoic acid (PFOA) in male rats. Toxicologist 11:95.
28. De Pinieux, G., Chariot, P., Ammi-Said, M., Louarn, F., Lejonc, J.L., Astier, A., Jacotot, B., and Gherardi, R. (1996). Lipid-lowering drugs and mitochondrial function: Effects of HMG-CoA reductase inhibitors on serum ubiquinones and blood lactate/pyruvate ratio. Br. J. Clin. Pharmacol. 42:333-337.
29. Doull, J., Cattley, R., Elcombe, E., Lake, B., Swenburg, J., Wilkinson, C., Williams, G., and van Gemert, M. (1999). A cancer risk assessment of di(2-ethylhexyl)phthalate: Application of the new U.S. EPA Risk Assessment Guidelines. Regul. Toxicol. Pharmacol. 29:327-357.
30. DuPont Company. (1965). Effects of fluorocarbon dispersing agents on the livers of rats and dogs. Haskell Laboratory unpublished report. Newark, DE. Available from GLK on request.
31. DuPont Company. (1979a). Acute dermal toxicity. Haskell Laboratory unpublished report. Newark, DE.
32. DuPont Company. (1979b). Eye irritation test in rabbits. Haskell Laboratory unpublished report. Newark, DE.
33. DuPont Company. (1981a). Ammonium perfluorooctanoate blood levels in the female rat. Haskell Laboratory unpublished report. Newark, DE.
34. DuPont Company. (1981b). Liver weight comparison in castrated and ovariectomized rats vs. normal rats. Haskell Laboratory unpublished report. Newark, DE.
35. 50 test in rats. Haskell Laboratory unpublished report. Newark, DE.
36. 50 test in rats. Haskell Laboratory unpublished report. Newark, DE.
37. 50 test in mice. Haskell Laboratory unpublished report. Newark, DE.
38. 50 test in guinea pigs. Haskell Laboratory unpublished report. Newark, DE.
39. DuPont Company. (1981g). Mouse feeding study - 14 day. Haskell Laboratory unpublished report. Newark, DE.
40. l4C-ammonium perfluorooctanoate in male and female rats, mice, hamsters, and rabbits. Haskell Laboratory unpublished report. Newark, DE.
41. 14C-labelled C-8 in the rat. Haskell Laboratory unpublished report. Newark, DE.
42. DuPont Company. (1982c). Effect of cholestyramine in the elimination of 14C-ammonium perfluorooctanoate in rats and mice. Haskell Laboratory unpublished report. Newark, DE.
43. DuPont Company. (1983a). Acute oral toxicity of FC-143 as a function of age. Haskell Laboratory unpublished report. Newark, DE.
44. DuPont Company. (1983b). APFO liver weights in rats and mice. Oral administration to males and females. Haskell Laboratory unpublished report. Newark, DE.
45. Eagon, P.K., Chandar, N., Epley, M.J., Elm, M.S., Brady, E.P., and Rao, K.N. (1994). Di(2-ethylhexyl)phthalate-induced changes in liver estrogen metabolism and hyperplasia. Int. J. Cancer 58:736-743.
46. Eagon, P.K., Elm, M.S., Epley, M.J., , Shinozuka, H., and Rao, K.N. (1996). Sex steroid metabolism and receptor status in hepatic hyperplasia and cancer in rats. Gastroenterology 110:1199-1207.
47. Elcombe, C.R., Bell, D.R., Elias, E., Hasmall, S.C., and Plant, N.J. (1997). Peroxisome proliferators: Species differences in response of primary hepatocyte cultures. Ann. NY Acad. Sci. 804:628-635.
48. Fan, L.Q., Cattley, R.C., and Corton, J.C. (1998). Tissue-specific induction of 17-beta-hydroxysteroid dehydrogenase type IV by peroxisome proliferator chemicals is dependent on the peroxisome proliferator-activated receptor-alpha. J. Endocrinol. 158:237-246.
49. Fitzgerald, J.E., Petrere, J.A., and de-la-Iglesia, F.A. (1987). Experimental studies on reproduction with the lipid-regulating agent gemfibrozil. Fundam. Appl. Toxicol. 8:454-464.
50. Flint, O.P., Masters, B.A., Gregg, R.E., and Durham, S.K. (1997). HMG-CoA reductase inhibitor-induced myotoxicity: Pravastatin and lovastatin inhibit the geranylation of low molecular weight proteins in neonatal rat muscle cell culture. Toxicol. Appl. Pharmacol. 145:99-100.
51. Fosslien, E. (2001). Review: Mitochondrial medicine - molecular pathology of defective oxidative phosphorylation. Ann. Clin. Lab. Sci. 31:25-67.
52. Gavin, C.E., Martin, N.P., and Schlosser, M.J. (1996). Absence of specific CCK-A binding sites on human pancreatic membranes. Toxicologist 30:334.
53. Gavin, C.E., Malnoske, J.A., White, J., and Schlosser, M.J. (1997). Species differences in expression of pancreatic cholecystokinin-A receptors. Toxicologist 36:1180.
54. Gibson, S.J., and Johnson, J.D. (1979). Absorption of FC-143-14C in rats after a single oral dose. Riker Laboratories, Inc., Subsidiary of 3M, St. Paul, MN, U.S. EPA Public Docket AR-226-0455, Washington, DC.
55. Gibson, J.P., Larson, E.J., Yarrington, J.T., Hook, R.H., Kariya, T., and Blohm, T.R. (1981). Toxicity and teratogenicity studies with the hypolipidemic drug RMI 14,514 in rats. Fundam. Appl. Toxicol. 1:19-25.
56. Gilliland, F.D. (1992). Fluorocarbons and human health: Studies in an occupational cohort. PhD dissertation, University of Minnesota, Minneapolis.
57. Gilliland, F.D., and Mandel, J.S. (1993). Mortality among employees of a perfluorooctanoic acid production plant. J. Occup. Med. 35:950-954.
58. Gilliland, F.D., and Mandel, J.S. (1996). Serum perfluorooctanoic acid and hepatic enzymes, lipoproteins, and cholesterol: A study of occupationally exposed men. Am. J. Ind. Med. 29:560-568.
59. Glass, A.R., and Swerdloff, R.S. (1980). Nutritional influences on sexual maturation in the rat. Fed. Proc. 39:2360-2364.
60. Glass, A.R., Harrison, R., and Swerdloff, R.S. (1976). Effect of undernutrition and amino acid deficiency on the timing of puberty in rats. Pediatr. Res. 10:951-955.
61. Goecke, C.M., Jarnot, B.M., and Reo, N.V. (1992). A comparative toxicological investigation of perfluorocarboxylic acids in rats by fluorine-19 NMR spectroscopy. Chem. Res. Toxicol. 5:512-519.
62. Goecke-Flora, C., and Reo, N. (1996). Influence of carbon chain length on the hepatic effects of perfluorinated fatty acids. Chem. Res. Toxicol. 9:689-695.
63. Gortner, E.G. (1981). Oral teratology study of T-2998CoC in rats. Safety Evaluation Laboratory and Riker Laboratories, Inc., Experiment No. 0681TR0110, December 1981. U.S. EPA Public Docket AR-226-0463.
64. Gortner, E.G. (1982). Oral teratology study of T-3141CoC in rabbits. Safety Evaluation Laboratory and Riker Laboratories, Inc., Experiment No. 0681TB0398, February 1982. U.S. EPA Public Docket AR-226-0465.
65. Graham, M.J., Wilson, S.A., Winham, M.A., Spencer, A.J., Rees, J.A., Old, S.L., and Bonner, F.W. (1994). Lack of peroxisome proliferation in marmoset liver following treatment with ciprofibrate for 3 years. Fundam. Appl. Toxicol. 22:58-64.
66. Green, S. (1995). PPAR: A mediator of peroxisome proliferator action. Mutat. Res. 333:101-109.
67. Griffith, F.D., and Long, J.E. (1980). Animal toxicity studies with ammonium perfluorooctanoate. Am. Ind. Hyg. Assoc. J. 41:576-583.
68. Gross, U., and Rudiger, S. (1991). Perfluorocarbons: Chemically inert but biologically active? J. Fluorine Chem. 53:155-161.
69. Guy, W.S. (1973). Fluorocompounds of human plasma: Analysis, prevalence, purification, and characterization. PhD dissertation, University of Rochester, Rochester, NY.
70. Han, X., Snow, T.A., Kemper, R.A., and Jepson, G.W. (2003). Binding of perfluorooctanoic acid to rat and human plasma proteins. Chem. Res. Toxicol. 16:775-781.
71. 2 production in intact liver. Toxicol. Lett. 60:61-68.
72. Hanhijärvi, H. (1988). A proposed species difference in the renal excretion of perfluorooctanoic acid in the beagle dog and rat. In New developments in biosciences: Their implications for laboratory animal science, eds. A.C. Beynen and H.A. Solleveld, pp. 404-412. Dordrecht: Martinus Nijhoff.
73. Hanhijärvi, H., Ophaug, R., and Singer, L. (1982). The sex related difference in perfluorooctanoate excretion in the rat. Proc. Soc. Exp. Biol. Med. 171:50-55.
74. Hanhijärvi, H., Ylinen, M., Kojo, A., and Kosma, V. (1987). Elimination and toxicity of perfluorooctanoic acid during subchronic administration in the Wistar rat. Pharmacol. Toxicol. 61:66-68.
75. Hansen, K.J., Clemen, L.A., Ellefson, M.E., and Johnson, H.O. (2001). Compound-specific, quantitative characterization of organic fluorochemicals in biological matrices. Environ. Sci. Technol. 35(4):766-770.
76. Haughom, B., and Spydevold, O. (1992). The mechanism underlying the hypolipemic effect of perfluorooctanoic acid (PFOA), perfluorooctane sulphonic acid (PFOSA) and clofibric acid. Biochim. Biophys. Acta 1128:65-72.
77. Hazleton, Inc. (1990). Primary dermal irritation/ corrosion study in rabbits. HLA number 91201740. U.S. EPA Public Docket AR-226-0666, Washington, DC.
78. Hazleton, Inc. (1995a). Mutagenicity test with T-6342 in the Salmonella-E. coli/mammalian microsome reverse mutation assay. Corning Hazleton, Inc. Final Report CHV Study No. 17073-0-409. December 14, 1995. U.S. EPA Public Docket AR-226-0436, Washington, DC.
79. Hazleton, Inc. (1995b). Mutagenicity test with T-6342 in an in vivo mouse micronucleus assay. Corning Hazleton, Inc. Final Report CHV Study No. 17073-0-455. December 14, (1995). U.S. EPA Public Docket AR-226-0435, Washington, DC.
80. Hazleton, Inc. (1995c). Acute dermal toxicity study of T-6342 in rabbits. Corning Hazleton, Inc. HWI 50800374. U.S. EPA Public Docket AR-226-0427, Washington, DC.
81. Hazleton, Inc. (1996a). Mutagenicity test with T-6564 in the Salmonella-E. coli/mammalian microsome reverse mutation assay with a confirmatory assay. Corning Hazleton, Inc. Final Report CHV Study No. 17750-0-409R. September 13, 1996. U.S. EPA Public Docket AR-226-0432, Washington, DC.
82. Hazleton, Inc. (1996b). Mutagenicity test with T-6342 measuring chromosomal aberrations in cultured whole blood lymphocytes with a confirmatory assay with multiple harvests. Corning Hazleton, Inc. Final Report CHV Study No. 17073-0-449CO. November 1, 1996. U.S. EPA Public Docket AR-226-0433, Washington, DC.
83. Hazleton, Inc. (1996c). Mutagenicity test with T-6564 measuring chromosomal aberrations in Chinese hamster ovary (CHO) cells with a confirmatory assay with multiple harvests. Corning Hazleton, Inc. Final Report CHV Study No. 17750-0-437CO. September 16, 1996. U.S. EPA Public Docket AR-226.
84. Hazleton, Inc. (1996d). Mutagenicity test with T-6342 measuring chromosomal aberrations in Chinese hamster ovary (CHO) cells with a confirmatory assay with multiple harvests. Corning Hazleton, Inc. Final Report CHV Study No. 17073-0-437CO. September 16, 1996. U.S. EPA Public Docket AR-226-0434, Washington, DC.
85. Hazleton, Inc. (1996e). Mutagenicity test with T-6564 in an in vivo mouse micronucleus assay. Corning Hazleton, Inc. Final Report CHV Study No. 17750-0-455, 1996. U.S. EPA Public Docket AR-226-0430, Washington, DC.
86. Hazleton, Inc. (1997). Acute oral toxicity study of T-6669 in rats. Corning Hazleton, Inc. CHW 61001760. U.S. EPA Public Docket AR-226-0420, Washington, DC.
87. Herrington, M.K., and Adrian, T.E. (1995). On the role of cholecystokinin in pancreatic cancer. Int. J. Pancreatol. 17:121-138.
88. Hosokawa, M., and Satoh, T. (1993). Differences in the induction of carboxylesterase isozymes in rat liver microsomes by perfluorinated fatty acids. Xenobiotica 23:1125-1133.
89. IARC. (1995). Peroxisome Proliferation and its role in carcinogenesis. World Health Organization, IARC Technical Report No. 24. Lyon, France.
90. Ikeda, T., Aiba, K., Fukuda, K., and Tanaka, M. (1985). The induction of peroxisome proliferation in rat liver by perfluorinated fatty acids, metabolically inert derivatives of fatty acids. J. Biochem. 98:475-482.
91. 14C. St. Paul, MN,: Riker Laboratories, Inc. U.S. ERA Public Docket AR-226-0457, Washington, DC.
92. 14C-potassium perfluorooctanesulfonate. Fundam. Appl. Toxicol. 4:972-976.
93. Just, W.W., Gorgas, K., Hartl, F.U., Heinemann, P., Salzer, M., and Schimassek, H. (1989). Biochemical effects and zonal heterogeneity of peroxisome proliferation induced by perfluorocarboxylic acids in rat liver. Hepatology 9:570-581.
94. Kawashima, Y., Uy-Yu, N., and Kozuka, H. (1989). Sex-related difference in the inductions by perfluorooctanoic acid of peroxisome β-oxidation, microsomal 1 -acylglycerolphosphocholine acyltransferase and cytosolic long-chain acyl-CoA hydrolase in rat liver. Biochem. J. 261:595-600.
95. Kawashima, Y., Suzuki, S., Kozuka, H., Sato, M., and Suzuki, Y. (1994). Effects of prolonged administration of perfluorooctanoic acid on hepatic activities of enzymes which detoxify peroxide and xenobiotics in the rat. Toxicology 93:85-97.
96. Keller, B.J., Marsman, D.S., Popp, J.A., and Thurman, R.G. (1992). Several nongenotoxic carcinogens uncouple mitochondrial oxidative phosphorylation. Biochim. Biophys. Acta 1102:237-244.
97. Kennedy, G.C., and Mitra, J. (1963). Body weight and food intake as initiating factors for puberty in the rat. J. Physiol 166:408-418.
98. Kennedy, G.L., Jr. (1985). Dermal toxicity of ammonium perfluorooctanoate. Toxicol. Appl. Pharmacol. 81:348-355.
99. Kennedy, G.L., Jr. (1987). Increase in mouse liver weight following feeding of ammonium perfluorooctanoate and related fluorochemicals. Toxicol. Lett. 39:295-300.
100. Kennedy, G.L., Jr., Hall, C.T., Brittelli, M.R., Barnes, J.R., and Chen, H.C. (1986). Inhalation toxicity of ammonium perfluorooctanoate. Food Chem. Toxicol. 24:1325-1329.
101. Kerstner-Wood, C., Coward, L., and Gorman, G. (2003). Protein binding of perfluoroobutane sulfonate, perfluorohexane sulfonate, perfluorooctane sulfonate, and perfluorooctanoate to plasma (human, rat, and monkey), and various human-derived plasma protein fractions. Unpublished report, Southern Research Institute, Study 9921.7. U.S. EPA Public Docket AR-226-1354, Washington, DC.
102. Klaunig, J.E., Babich, M.A., Baetcke, K.P., Cook, J.C., Corton, J.C., David, R.M., DeLuca, J.G., Lai, D.Y., McKee, R.H., Peters, J.M., Roberts, R.A., and Fenner-Crisp, P.A. (2003). PPAR alpha agonist-induced rodent tumors: Modes of action and human relevance. Crit. Rev. Toxicol. 33:655-780.
103. Klevens, H.B., and Ellenbogen, E. (1954). Protein-fluoroacid interaction bovine serum albumin perfluoro-octanoic acid. Discuss. Faraday Soc. 18:277-288.
104. Kojo, A., Hanhijärvi, H., Ylinen, M., and Kosma, V.M. (1986). Toxicity and kinetics of perfluoro-octanoic acid in the Wistar Rat. Arch. Toxicol. Suppl. 9:465-468.
105. Kudo, N., Mizuguchi, H., Yamamoto, A., and Kawashima, Y. (1999). Alterations by perfluorooctanoic acid of glycerolipid metabolism in rat liver. Chem. Biol. Interact. 118:69-83.
106. Kudo, N., Suzuki, E., Katakuva, M., Ohmori, K., Noshiro, R., and Kawashima, Y. (2001). Comparison of elimination between perfluorinated fatty acids with different carbon chain length in rats. Chem.-Biol. Interact. 134:203-216.
107. Kudo, N., Katakura, M., Sato, Y., and Kawashima, Y. (2002). Sex hormone-regulated renal transport of perfluorooctanoic acid. Chem. Biol. Interact. 139:301-316.
108. Kurata, Y., Kidachi, F., Yokoyama, M., Toyota, N., Tsuchitani, M., and Katoh, M. (1998). Subchronic toxicity of di(2-ethylhexyl) phthalate in common marmosets: Lack of peroxisomal proliferation, testicular atrophy, or pancreatic acinar cell hyperplasia. Toxicol. Sci. 42:49-56.
109. Kuslikis, B.I., Vanden Heuvel, J.P., and Peterson, R.E. (1992). Lack of evidence for perfluorodecanoyl-or perfluorooctanoyl-coenzyme A formation in male and female rats. Biochem. Toxicol. 7:25-29.
110. Lake, B.G. (1995). Mechanisms of hepatocarcinogenicity of peroxisome-proliferating drugs and chemicals. Annu. Rev. Pharmacol. Toxicol. 35:483-507.
111. Lewis, E.M., Barnett, J.F., Jr., Freshwater, L., Hoberman, A.M., and Christian, M.S. (2002). Sexual maturation data for Cr1 Sprague-Dawley rats: Criteria and confounding factors. Drug Chem. Toxicol. 25:437-458.
112. Litton Bionetics. (1978). Mutagenic evaluation of T-2015 CoC in the Ames Salmonella microsome plate test. Final Report LBI Project No. 20838, February 1978. U.S. EPA Public Docket AR-226-0429, Washington, DC.
113. Liu, R.C.M., Hahn, C., and Hunt, M.E. (1996a). The direct effect of hepatic peroxisome proliferators on rat Leydig cell function in vitro. Fundam. Appl. Toxicol. 30:102-108.
114. Liu, R.C.M., Hum, M.E., Cook, J.C., and Biegel, L.B. (1996b). Effect of the peroxisome proliferator, ammonium perfluorooctanoate (APFO), on hepatic aromatase activity in adult male Crl:CDBR (CD) rats. Fundam. Appl. Toxicol. 30:220-228.
115. Liu, S.C., Sanfilippo, B., Perroteau, I., Derynck, E., Salomon, D.S., and Kidwell, W.R. (1987). Expression of transforming growth factor (TGFα) in differentiated rat mammary tumors: Estrogen induction of TGFα production. Mol. Endocrinol. 1:683-692.
116. Malinverno, G., Rusch, G.M., Millischer, R.J., Hughes, E.W., Schroeder, R.E., and Coombs, D.W. (1996). Inhalation teratology and reproduction studies with 1,1-dichloro-2,2,2-trifluoroethane (HCFC-123). Fundam. Appl. Toxicol. 34:276-287.
117. Maloney, E.K., and Waxman, D.J. (1999). Transactivation of PPARα and PPARγ by structurally diverse environmental chemicals. Toxicol. Appl. Pharmacol. 161:209-218.
118. Marty, M.S., Crissman, J.W., and Carney, E.W. (1999). Evaluation of the EDSTAC female pubertal assay in CD rats using 17 β-estradiol, steroid biosynthesis inhibitors, and a thyroid inhibitor. Toxicol. Sci. 52:269-277.
119. Marty, M.S., Crissman, J.W., and Carney E.W. (2001a). Evaluation of the male pubertal onset assay to detect testosterone and steroid biosynthesis inhibitors in CD rats. Toxicol. Sci. 60:285-295.
120. Marty, M.S., Crissman, J.W., and Carney, E.W. (2001b). Evaluation of the male pubertal onset assay's ability to detect thyroid inhibitors and dopaminergic agents. Toxicol. Sci. 60:62-76.
121. Marty, M.S., Johnson, K.A., and Carney, E.W. (2001c). Effect of feed restriction on Hershberger and pubertal male assay endpoints. Toxicologist 60:223.
122. Moore, G.E. (2001). H-24921: Dermal sensitization test - Buehler method. Product Safety Labs, Study No. 11321. December 17. Dayton, NJ. Available from GLK on request.
123. Moroi, Y., Yano, H., Shibata, O., and Yonemitsu, T. (2001). Determination of acidity constants of perfluoroalkanoic acids. Bull. Chem. Soc. Jpn. 74:667-672.
124. Nilsson, R., Beije, B., Preat, V., Erixon, K. and Ramel, C. (1991). On the mechanism of the hepatocarcinogenicity of peroxisome proliferators. Chem.-Biol. Interact. 78:235-250.
125. Noker, P. (2003). A pharmacokinetic study of potassium perfluoroodanoate in the cynomologus monkey. Southern Research Institute Study ID: 99214. South Research Institute, submitted to U.S. EPA AR 226-1228, Washington, DC.
126. Nordby, G.L., and Luck, J.M. (1956). Perfluorooctanoic acid interactions with human serum albumin. J. Biol. Chem. 219:399-404.
127. Notox. (2002). Evaluation of the ability of T-7524 to induce chromosomal aberrations in cultured peripheral human lymphocytes. Notox Project No. 292062. Hertogenbosch, the Netherlands. U.S. EPA Public Docket AR-226-0404, Washington, DC.
128. Obourn, J.D., Frame, S.R., Bell, R.H., Longnecker, D.S., Elliott, G.S., and Cook, J.C. (1997). Mechanisms for the pancreatic oncogenic effects of the peroxisome proliferator Wyeth-14,643. Toxicol. Appl. Pharmacol. 145:425-436.
129. Obraztsov, V.V., Kabalnov, A.S., Makarov, K.M., Gross, U. Radeck, W., and Rudiger, S. (1993). On the interaction of perfluorochemical emulsions with liver microsomal membranes. J. Fluorine Chem. 63:101-111.
130. Ohmori, K., Kudo, N., Katayama, K., and Kawashima, Y. (2003). Comparison of the toxicokinetics between perfluorocarboxylic acids with different carbon chain length. Toxicology 184:135-140.
131. Ohmura, T., Katyal, S.L., Locker, J., Ledda-Columbano, G.M., Columbano, A., and Shinozuka, H. (1997). Induction of cellular DNA synthesis in the pancreas and kidneys of rats by peroxisome proliferators, 9-cis retinoic acid, and 3,3′,5-triiodo-L-thyronine. Cancer Res. 57:795-798.
132. Olsen, G.W., Gilliland, F.D., Burlew, M.M., Burris, J.M., Mandel, J.S., and Mandel, J.H. (1998). An epidemiologic investigation of reproductive hormones in men with occupational exposure to perfluorooctanoic acid. J. Occup. Environ. Med. 40:614-620.
133. Olsen, G.W., Burris, J.M., Burlew, M.M., and Mandel, J.H. (2000). Plasma cholecystokinin and hepatic enzymes, cholesterol and lipoproteins in ammonium perfluorooctanoate production workers. Drug Chem. Toxicol. 23:603-620.
134. Olsen, G.W., Church, T., Miller, J.P., Hansen, K.J., Lundberg, J.K., Armitage, J., Herron, R., Medhdizadehkashi, Z., Nobiletti, J., O'Neill, M., Mandel, J.H., and Zobel, L.R. (2003a). Perfluorooctanesulfoante (PFOS) and other fluorochemicals in the serum of American Red Cross adult blood donors. Environ. Health Perspec. 111:1892-1901.
135. Olsen, G.W., Hansen, K.J., Stevenson, L.A., Burris, J.M., and Mandel, J.H. (2003b). Human donor liver and serum concentrations of perfluorooctanesulfonate (PFOS) and other perfluorochemicals. Environ. Sci. Technol. 37:888-891.
136. Olsen, G.W., Butenhoff, J.L., and Mandel, J.H. (2003c). Assessment of lipid, hepatic and thyroid function in relation to an occupational biologic limit value for perfluorooctanoate. U.S. EPA Public Docket AR-226-1351, Washington, DC.
137. Olsen, G.W., Burris, J.M., Burlew, M.M., and Mandel, J.H. (2003d). Epidemiological assessment of worker serum perfluorooctanesulfoante (PFOS) and perfluorooctanoate (PFOA) concentrations and medical surveillance examinations. J. Occup. Environ. Med. 45:260-270.
138. Olsen, G.W., Church, T.R., Larson, E.B., van Belle, G., Lundberg, J.K., Burris, J.M., Mandel, J.H., and Zobel, L.R. (2004a). Serum concentrations of perfluorooctanesulfonate (PFOS) and other fluorochemicals in an elderly population from Seattle, Washington. Chemosphere 54:1599-1611.
139. Olsen, G.W., Church, T.R., Hansen, K.J., Burris, J.M., Butenhoff, J.L., Mandel, J.H., and Zobel, L.R. (2004b). Quantitative evaluation of perfluorooctanesulfonate (PFOS) and other fluorochemicals in the serum of children. J. Children's Health 2:1-24.
140. Olson, C.T., and Andersen, M.E. (1983). The acute toxicity of perfluorooctanoic and perfluorodecanoic acids in male rats and effects on tissue fatty acids. Toxicol. Appl. Pharmacol. 70:362-372.
141. Omar, M.A., Wilson, J.P., and Cox, T.S. (2001). Rhabdomyelosis and HMG-CoA reductase inhibitors. Ann. Pharmacother. 35:1096-1107.
142. Ophaug, R.H., and Singer, L. (1980). Metabolic handling of perfluorooctanoic acid in rats. Proc. Soc. Exp. Biol. Med. 163:19-23.
143. Palmer, C.N.A., Hsu, M.H., Griffin, K.J., Raucy, J.L., and Johnson, E.F. (1998). Peroxisome proliferator activated receptor-α expression in human liver. Mol. Pharmacol. 53:14-22.
144. Panaretakis, T., Shabalina, I.G., Grander, D., Shoshan, M.C., and DePierre, J.W. (2001). Reactive oxygen species and mitochondria mediate the induction of apoptosis in human hepatoma HepG2 cells by the rodent peroxisome proliferator and hepatocarcinogen, perfluorooctanoic acid. Toxicol. Appl. Phamacol. 173:56-64.
145. Pandol, S.J. (1998). Pancreatic physiology and secretory testing. In Gastrointestinal and liver diseases, vol. 1, eds. M. Sleisenger and J.S. Fordtran, pp.771-782. Philadelphia: W.B. Saunders.
146. Pastoor, T.P., Lee, K.P., Perri, M.A., and Gillies, P.J. (1987). Biochemical and morphological studies of ammonium perfluorooctanoate-induced hepatomegaly and peroxisome proliferation. Exp. Mol. Pathol. 47:98-109.
147. Perkins, R.G. (1992). Investigation of ammonium perfluorooctanoate effect on hormone levels and peroxisomal proliferation in the rat. Toxicologist 12:52.
148. Permadi, H., Lundgren, B., Andersson, K., and DePierre, J.W. (1992). Effects of perfluoro fatty acids on xenobiotic metabolizing enzymes which detoxify reactive forms of oxygen and lipid peroxidation in mouse liver. Biochem. Pharmacol. 44:1183-1191.
149. Peters, J.M., Cattley, R.C., and Gonzales, F.J. (1997). Role of PPARα in the mechanism of action of the non-genotoxic carcinogen WY-14643. Carcinogenesis 18:2029-2033.
150. Peterson, R.E., Kuslikis, B.I., and Vanden Heuvel, J.P. (1991). Protein acylation by the peroxisome proliferators perfluorodecanoic acid (PFDA) and perfluorooctanoic acid (PFOA) in rats. Toxicologist 11:185.
151. Pugh, G., Isenberg, J.S., Kamendolis, L.M., Ackley, D.C., Clare, L.J., Brown, R., Lington, A.W., Smith, J.H., and Klaasen, J.E. (2000). Effects of di-isononyl phthalate, di-2-ethylhexyl phthalate and clofibrate in cynomologus monkeys. Toxicol. Sci. 56:181-188.
152. Reddy, J.K., and Rao, M.S. (1977). Malignant tumors in rats fed nafenopin, a hepatic peroxisome proliferator. J. Natl. Cancer Inst. 59:1645-1650.
153. Reddy, J.K., and Rao, M.S. (1995). Postulated mechanisms of carcinogenicity mediated by peroxisome proliferators. IARC Technical Report No. 24, pp. 41-53. Lyon, France.
154. Riker. (1981). Final Report: Repeat Application 28-Day Percutaneous Absorption Study with T-2618 CoC in Albino Rabbits. Riker Laboratories Report 09790AB0485, March 15, 1981. U.S. EPA Public Docket AR-226-0446, Washington, DC.
155. Riker. (1987). Two year oral (diet) toxicity/ carcinogenicity study of fluorochemical FC-143 in rats. Riker Laboratories, Inc., Experiment No. 0281CR0012, August 29, 1987. U.S. EPA Public Docket AR-226-0437, Washington, DC.
156. Ronnekleiv, O.K., Ojeda, S.R., and McCann, S.M. (1978). Undernutrition, puberty, and the development of estrogen positive feedback in the female rat. Biol. Reprod. 19:414-424.
157. Schottenfeld, D. (1996). Testicular cancer. In Cancer epidemiology and prevention, eds. D. Schottenfeld and J.F. Fraumeni, pp. 1207-1219. New York: Oxford University Press.
158. Sohlenius, A.K., Andersson, K., and DePierre, J. (1992). The effects of perfluorooctanoic acid on hepatic peroxisome proliferation and related parameters show no sex-related differences in mice. Biochem. J. 265:779-783.
159. Staples, R.E. (1985). Improper interpretation of data concerning teratogenicity: A case report. In Prevention of physical and mental congenital defects, Part C: Basic and medical science, education and Future strategies, pp. 161-163. New York: Alan R. Liss, Inc.
160. Staples, R.E., Burgess, B.A., and Kerns, W.D. (1984). The embryo-fetal toxicity and teratogenic potential of ammonium perfluorooctanoate (APFO) in the rat. Fundam. Appl. Toxicol. 4:429-440.
161. Starkov, A.A., and Wallace, K.B. (2002). Structural determinants of fluorochemical-induced mitochondrial dysfunction. Toxicol. Sci. 66:244-252.
162. Stoker, T.E., Laws, S.C., Guidici, D.L., and Cooper, R.L. (2000a). The effect of atrazine on puberty in male wistar rats: An evaluation in the protocol for assessment of pubertal development and thyroid function. Toxicol. Sci. 58:50-59.
163. Stoker, T.E., Parks, L.G., Gray, L.E., and Cooper, R.L. (2000b). Endocrine-disrupting chemicals: Prepubertal exposures and effects on sexual
164. Stone Research Laboratories. (1981). An assay of cell transformation and cytotoxicity in the C3H 10T 1/2 clonal cell line for the test chemical T-2942 CoC. Environmental Pathology Laboratory, Stone Research Laboratories, University of Minnesota, March 5, 1981. U.S. EPA Public Docket AR-226-0428, Washington, DC.
165. Svoboda, D.J., and Azarnoff, D.L. (1979). Tumors in male rats fed ethyl chlorophenoxyisobutyrate, a hypolipidemic drug. Cancer Res. 39:3419-3428.
166. Takagi, A., Sai, K., Umemura, T., Hasegawa, R., and Kurokawa, Y. (1991). Short-term exposure to the peroxisome proliferators, perfluorooctanoic acid and perfluorodecanoic acid, causes significant increase of 8-hydroxydeoxyguanosine in liver DNA of rats. Cancer Lett. 57:55-60.
167. Takagi, A., Sai, K., Ummemura, T., Hasegawa, R., and Kurokawa, Y. (1992). Hepatomegaly is an early biomarker for hepatocarcinogenesis induced by peroxisome proliferators. J. Environ. Toxicol. Pathol. 11:145-149.
168. Taves, D. (1968a). Evidence that there are two forms of fluorine in human serum. Nature 217:1050-1051.
169. Taves, D. (1968b). Electrophoretic mobility of serum fluoride. Nature 220:582-583.
170. Taves, D., Guy, W., and Brey, W. (1976). Organic fluorocarbons in human plasma: Prevalence and characterization. In Biochemistry involving carbon-fluorine bonds, ed. R. Filler, pp. 117-134. Washington, DC: American Chemical Society.
171. Toxicon. (2002). CHO/HGPRT Forward mutation assay - ISO Toxicon Final Report: 01-7019-G1. U.S. EPA Public Docket AR-226-1101, Washington, DC.
172. Tucker, M.J., and Orton, T.C. (1993). Toxicological studies in primates with three fibrates. In Peroxisomes: Biology and importance in toxicology and medicine, eds. G. Gibson and B. Lake, pp. 425-447. London: Taylor & Francis.
173. Ubel, F.A., Sorenson, S.D., and Roach, D.E. (1980). Health status of plant workers exposed to fluorochemicals-a preliminary report. Am. Ind. Hyg. Assoc. J. 41:584-589.
174. Ullrich, V., and Diehl, H. (1971). Uncoupling of monooxygenation and electron transport by fluorocarbons in liver microsomes. Eur. J. Biochem. 20:509-512.
175. Upham, B.L., Deocampo, N.D., Wurl, B., and Trosko, J.E. (1998). Inhibition of gap junctional intercellular communication by perfluorinated fatty acids is dependent on the chain length of the fluorinated tail. Int. J. Cancer 78:491-495.
176. Vanden Heuvel, J.P. (1999). Peroxisome proliferator-activated receptors (PPARs) and carcinogenesis. Toxicol. Sci. 47:1-8.
177. Vanden Heuvel, J., Kuslikis, B., and Van Rafelghem, M. (1991). Tissue distribution, metabolism, and elimination of perfluorooctanoic acid in male and female rats. Biochem. Toxicol. 6:83-92.
178. Vanden Heuvel, J.P., Kuslikis, B.I., and Peterson, R.E. (1992a). Covalent binding of perfluorinated fatty acids to proteins in the plasma, liver and testes of rats. Chem.-Biol. Interact. 82:317-328.
179. Vanden Heuvel, J., Davis, J., Sommers, R., and Peterson, R. (1992b). Renal excretion of perfluorooctanoic acid in male rats: Inhibitory effect of testosterone. Biochem. Toxicol. 7:31-36.
180. Ward, J.M., Peters, J.M., Perella, C.M., and Gonzalez, F.J. (1998). Receptor and non-receptor-mediated organ-specific toxicity of di(2-ethylhexyl) phthalate (DEHP) in peroxisome proliferator-activated receptor α-null mice. Toxicol. Pathol. 26:240-246.
181. Widdowson, E.M., and McCance, R.A. (1960). Some effects of accelerating growth. I. General somatic development. Proc. R. Soc. B 152:188-206.
182. Yang, Q., Xie, Y., and DePierre, J.W. (2000). Effects of peroxisome proliferators in the thymus and spleen of mice. Clin. Exp. Immunol. 122:219-226.
183. Yang, Q., Xie, Y., Ericksson, A.M., Nelson, B.D., and DePierre, J.W. (2001). Further evidence for the involvement of inhibition of cell proliferation and development in thymic and splenic atrophy induced by the peroxisome proliferator perfluorooctanoic acid in mice. Biochem. Pharmacol. 62:1133-1140.
184. Yang, Q., Xie, Y., Alexson, S.E.H., Nelson, B.D., and DePierre, J.W. (2002a). Involvement of the peroxisome proliferator-activated receptor alpha in the immunomodulation caused by peroxisome proliferators in mice. Biochem. Pharmacol. 63:1893-1900.
185. Yang, Q., Abedi-Valugerdi, M., Xie, Y., Zhao, X., Moller, G., Nelson, B.D., and DePierre, J.W. (2002b). Potent suppression of the adaptive immune response in mice upon dietary exposure to the potent peroxisome proliferator, perfluorooctanoic acid. Int. Immunopharmacol. 2:389-397.
186. Ylinen, M., Hanhijärvi, H., Jaakonaho, J., and Peura, P. (1989). Stimulation by oestradiol of the urinary excretion of perfluorooctanoic acid in the male rat. Pharmacol. Toxicol. 65:274-277.
187. Ylinen, M., Kojo, A., Hanhijärvi, H., and Peura, P. (1990). Deposition of perfluorooctanoic acid in the rat after single and subchronic administration. Bull. Environ. Contam. Toxicol. 44:46-53.